WCN26-3838 REAL-WORLD EVIDENCE OF THE INITIAL DIP ADN CHANGES IN eGFR SLOPE AFTER SGLT2 INHIBITOR ADMINISTRATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE

Read full text Summarise with VIRAT
Authors: Noriko Inoue, Junichi Hoshino, Akinari Sekine, Eiko Hasegawa, Kiho Tanaka, Masayuki Yamanouchi, Tatsuya Suwabe, Naoki Sawa, Yoshifumi Ubara, Takehiko Wada, Koichi Tamura
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have been shown to provide renal protection in patients with chronic kidney disease (CKD), regardless of their diabetes status. After initiation, a transient decrease in estimated glomerular filtration rate (eGFR), known as the “initial dip,” is commonly observed; however, its clinical significance remains uncertain. The aim of this study is to identify the factors that influence the magnitude of initial dip, to elucidate its relationship with long-term renal outcomes and changes in eGFR slope subsequent to SGLT2i initiation, and to investigate the factors associated with improvement in eGFR slope after SGLT2i initiation..

Fields of Study & Subjects

Chronic Kidney Disease and Diabetes Diabetes Treatment and Management Acute Kidney Injury Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104611–104611
Publication date
25 March 2026
Language
EN